Thematic Take

Powered by

Christopher Papadopoullos, principal analyst at GlobalData

Foreword: A growing sense of urgency in ESG 

At GlobalData, we define a theme as any disruptive trend or technology that keeps a business leader awake at night. Companies that invest in the right themes become success stories. Those that miss the essential themes in their industry end up as failures. 

ESG is one of the most important themes of the decade. The Paris Agreement, the global agreement to limit global warming to 2°C above pre-industrial levels, has been signed by 195 countries, including the US and China. As part of the agreement, many signatories need to reduce their emissions to meet 2030 emissions targets, which is creating a growing sense of urgency as we move closer to the end of the decade.  

This pressure feeds through to corporates, which must now navigate mandatory sustainability reporting, new rules on environmental due diligence, emissions pricing, and financial incentives to use more sustainable sources of energy.  

Many major corporates are well ahead of the regulation and have already started investing in improving the environmental impact of their business. They are changing the way they manage environmental data so that they can bring it up to the robustness of regulated financial data. They are investing in technological solutions to reduce their carbon footprint and understand the emissions generated by their supply chain and use of their product or service. Many corporates are insisting that suppliers and key business partners have commitments to cut their emissions.  

Key to all of this is establishing the right governance structures early on to lay the foundations for long-term success. Developing and executing a successful ESG strategy is now going to require the involvement of more teams and senior figures. 

While ESG drives internal business transformation, companies need to rein in ESG-related marketing and external communications. Terms like ‘climate neutral’ and ‘eco-friendly’ now invite unwanted attention from regulators keen to crack down on greenwashing as well as the anti-ESG movement. The anti-ESG movement has become especially strong in the US, where ESG has become a hot political topic, and poses a risk to any company that pushes ESG in its marketing. 

Go to article: Home | Lula’s progress plan for Brazil: A year onGo to article: Editor's letterGo to article: ContentsGo to article: Mimotopes Company InsightGo to article: MimotopesGo to article: XylemGo to article: BriefingGo to article: News in NumbersGo to article: Latest NewsGo to article: Latest DealsGo to article: Project UpdatesGo to article: Trends & InsightGo to article: phasetwoGo to article: Datwyler Company InsightGo to article: DatwylerGo to article: In DepthGo to article: Lula’s progress plan for Brazil: A year on Go to article: How sham patents are hurting the pharma industryGo to article: Tracking the opioid lawsuit settlements amidst calls for oversight Go to article: Cell and gene therapy landscape in the USGo to article: Q&A: Cell and gene therapy value assessments need a rework to allow access Go to article: Pharmaceutical discovery through a gravitational lens Go to article: Thematic Take: ESGGo to article: Thematic Take: contentsGo to article: Foreword: A growing sense of urgency in ESG Go to article: ESG 1.0 is over – get ready for ESG 2.0 Go to article: ESG becomes mandatory: how to prepareGo to article: Theme timeline: the past, present and future of ESG Go to article: Net-zero strategies for the pharma sector Go to article: Leading pharma companies and initiatives in the race for net zeroGo to article: GlobalData’s Christopher Papadopoullos on net-zero strategy for businesses Go to article: 38% of companies lack an ESG strategy – GlobalData survey Go to article: Sustainability challenges in rare disease trials remain, but change is happeningGo to article: ESCMID 2024: The infectious consequences of climate change Go to article: Bring your own device: How patients own tech is being used in clinical trialsGo to article: Can pharma overcome generative AI’s bias problem?Go to article: China-US tensions are spilling into the biotech sector Go to article: Japanese patients among least empowered in the developed worldGo to article: World Air Quality Report: what are the health impacts and where is it worst? Go to article: Why has New Zealand U-turned on the world’s first smoking ban?Go to article: Microplastics in placentas: how serious is the problem? Go to article: Deal activity related to ESG in the pharma industry since 2021Go to article: GlobalData Thematic IntelligenceGo to article: Sponsored SupplementsGo to article: BEA TechnologiesGo to article: CytivaGo to article: ListingsGo to article: EventsGo to article: Innovation RankingsGo to article: Buyer's GuidesGo to article: Next issue